Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Feb;31(2):343–345. doi: 10.1128/aac.31.2.343

In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

A L Barry, C Thornsberry, R N Jones
PMCID: PMC174723  PMID: 2952064

Abstract

A new macrolide (A-56268) was found to be approximately twice as active as erythromycin and four to eight times more active than roxithromycin. All three macrolides were similar in their potency against anaerobes. Human plasma enhanced the antistaphylococcal activity of A-56268 and erythromycin but reduced the activities of roxithromycin and clindamycin.

Full text

PDF
343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlam T., Neu H. C. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Apr;25(4):529–531. doi: 10.1128/aac.25.4.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biddle J. W., Thornsberry C. In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1979 Feb;15(2):243–245. doi: 10.1128/aac.15.2.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fernandes P. B., Bailer R., Swanson R., Hanson C. W., McDonald E., Ramer N., Hardy D., Shipkowitz N., Bower R. R., Gade E. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986 Dec;30(6):865–873. doi: 10.1128/aac.30.6.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hansen S. L., Swomley P., Drusano G. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin. Antimicrob Agents Chemother. 1981 Feb;19(2):335–336. doi: 10.1128/aac.19.2.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Barry A. L., Thornsberry C. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother. 1983 Aug;24(2):209–215. doi: 10.1128/aac.24.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jorgensen J. H., Redding J. S., Howell A. W. In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1986 May;29(5):921–922. doi: 10.1128/aac.29.5.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kurzynski T. A., Yrios J. W., Helstad A. G., Field C. R. Aerobically incubated thioglycolate broth disk method for antibiotic susceptibility testing of anaerobes. Antimicrob Agents Chemother. 1976 Oct;10(4):727–732. doi: 10.1128/aac.10.4.727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rosenblatt J. E., Schoenknecht F. Effect of several components of anaerobic incubation on antibiotic susceptibility test results. Antimicrob Agents Chemother. 1972 May;1(5):433–440. doi: 10.1128/aac.1.5.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Washington J. A., 2nd, Wilson W. R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin Proc. 1985 Mar;60(3):189–203. doi: 10.1016/s0025-6196(12)60219-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES